Drug combination delays worsening of disease in women with recurrent ovarian cancer

For many women with ovarian cancer that has recurred after initial treatment, a two-drug combination can significantly extend the time that the disease is kept in check, a phase 2 clinical trial led by Dana-Farber Cancer Institute investigators and supported by the National Cancer Institute shows. In a report on the trial in the online edition of The Lancet Oncology, researchers compared the drugs cediranib and olaparib, versus olaparib alone, in their ability to stall the advance of ovarian cancer in women with a recurrent form of the disease that responds to platinum-based chemotherapy agents. Read more here.